ATE517910T1 - NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG - Google Patents

NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG

Info

Publication number
ATE517910T1
ATE517910T1 AT07006986T AT07006986T ATE517910T1 AT E517910 T1 ATE517910 T1 AT E517910T1 AT 07006986 T AT07006986 T AT 07006986T AT 07006986 T AT07006986 T AT 07006986T AT E517910 T1 ATE517910 T1 AT E517910T1
Authority
AT
Austria
Prior art keywords
urokinase
blood vessel
vessel formation
covalent inhibitors
activity
Prior art date
Application number
AT07006986T
Other languages
English (en)
Inventor
Joseph Edward Semple
Michael I Weinhouse
Odile Esther Levy
Edwin L Madison
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Application granted granted Critical
Publication of ATE517910T1 publication Critical patent/ATE517910T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069Ser-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07006986T 2000-08-11 2000-12-07 NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG ATE517910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63748300A 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
ATE517910T1 true ATE517910T1 (de) 2011-08-15

Family

ID=24556134

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07006986T ATE517910T1 (de) 2000-08-11 2000-12-07 NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG
AT00126874T ATE360028T1 (de) 2000-08-11 2000-12-07 Nicht-kovalente urokinase-und angiogenese- inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00126874T ATE360028T1 (de) 2000-08-11 2000-12-07 Nicht-kovalente urokinase-und angiogenese- inhibitoren

Country Status (8)

Country Link
US (1) US6586405B2 (de)
EP (2) EP1808440B1 (de)
KR (1) KR100879673B1 (de)
AT (2) ATE517910T1 (de)
DE (1) DE60034447T2 (de)
ES (1) ES2285989T3 (de)
IL (1) IL149042A (de)
ZA (1) ZA200202825B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7001887B2 (en) * 2001-02-02 2006-02-21 Chugai Seiyaku Kabushiki Kaisha Peptide derivatives
WO2002064140A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (de) 2001-03-22 2004-12-15 Dendreon Corp Serinprotease cvsp14 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
WO2002077267A2 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
KR20040080940A (ko) * 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
WO2003048127A1 (en) * 2001-12-04 2003-06-12 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
ATE399175T1 (de) * 2002-03-11 2008-07-15 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
US7019019B2 (en) * 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
DE602006009257D1 (de) 2005-06-24 2009-10-29 Wilex Ag Verwendung von urokinase-inhibitoren zur behandlunklerose (als)
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
US20100261662A1 (en) * 2009-04-09 2010-10-14 Endologix, Inc. Utilization of mural thrombus for local drug delivery into vascular tissue
DE102009022794A1 (de) * 2009-05-27 2010-12-02 Philipps-Universität Marburg Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel
WO2011044455A1 (en) * 2009-10-09 2011-04-14 Vatrix Medical, Inc. In vivo chemical stabilization of vulnerable plaque
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
EP2960232A1 (de) * 2014-06-25 2015-12-30 DSM IP Assets B.V. Verfahren zur Herstellung eines Dipeptidderivats
US9777116B2 (en) 2014-10-16 2017-10-03 International Business Machines Corporation Porous/nanoporous PHT
CN113135842A (zh) * 2018-09-25 2021-07-20 四川什邡市三高生化实业有限公司 一种o-叔丁基-l-丝氨酸甲酯及o-叔丁基-l-丝氨酸水溶液的制备方法
JP2022541398A (ja) * 2019-07-08 2022-09-26 リゾルート,インコーポレイティド 血漿カリクレイン阻害薬の調製プロセス
KR20220050942A (ko) * 2019-08-21 2022-04-25 칼비스타 파마슈티컬즈 리미티드 효소 저해제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
KR19980702112A (ko) 1995-02-10 1998-07-15 페라 스타르크,요헨 카르크 트롬빈 억제제
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
SK14232001A3 (sk) 1999-04-09 2002-06-04 Basf Aktiengesellschaft Nízkomolekulové inhibítory komplementárnych proteáz
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa

Also Published As

Publication number Publication date
EP1182207A3 (de) 2002-09-04
EP1182207A2 (de) 2002-02-27
US20020037857A1 (en) 2002-03-28
ES2285989T3 (es) 2007-12-01
KR20020063562A (ko) 2002-08-03
IL149042A (en) 2011-01-31
EP1808440A1 (de) 2007-07-18
ZA200202825B (en) 2003-07-10
EP1182207B1 (de) 2007-04-18
DE60034447D1 (de) 2007-05-31
DE60034447T2 (de) 2008-02-14
KR100879673B1 (ko) 2009-01-21
ATE360028T1 (de) 2007-05-15
EP1808440B1 (de) 2011-07-27
US6586405B2 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
ATE517910T1 (de) NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG
WO2000005245A3 (en) Inhibitors of urokinase and blood vessel formation
Sang et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases
ATE150308T1 (de) Hemmung von thrombin
WO2002014349A3 (en) Non-covalent inhibitors of urokinase and blood vessel formation
EA200200333A1 (ru) Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
HUP0105077A2 (hu) Szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
DE69430816D1 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
DE69427800D1 (de) Methode zur Hemmung der Endometriose
EA200101077A1 (ru) Композиция для профилактики или лечения слабоумия, включающая производное гидроксикоричной кислоты или экстракт растения рода angelicae, содержащий его
DE69428325D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
DE69426855D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung des Knorpelabbaus
DE69430940T2 (de) Methode zur Behandlung von resistenten Neoplasmen
DE69612540T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE332697T1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
DE69427807T2 (de) Hemmung von Hirsutismus und Alopecia bei Frauen
DE69911373D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE409469T1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
ATE220665T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties